The effects of 20-kDa human placental GH in male and female GH deficient mice: an improved human GH?

Clicks: 159
ID: 114943
2001
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #99 of 213 articles by views in endocrinology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 213 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract A rare 20K isoform of GH-V (here abbreviated GHv) was discovered in 1998. To date, only one research article has characterized this isoform in vivo observing that GHv treatment in male high-fat fed rats had several GH-like activities but unlike GH lacked diabetogenic and lactogenic activities and failed to increase IGF-1 or body length. Therefore, the current study was conducted to further characterize the in vivo activities of GHv in a separate species and in a GH deficient model (GH-/- mice) and with both sexes represented. GHv treated GH-/- mice had significant increases to serum IGF-1, femur length, body length, body weight and lean body mass and reduced body fat mass similar to mice receiving GH treatment. GH treatment increased circulating insulin levels and impaired insulin sensitivity, in contrast, both measures were unchanged in GHv treated mice. Since GHv lacks prolactin receptor (PRLR) binding activity, we tested the ability of GH and GHv to stimulate proliferation of human cancer cell lines and found that GHv has a decreased proliferative response in cancers with high PRLR. Our findings demonstrate that GHv can stimulate IGF-1 and subsequent longitudinal body growth in GH deficient mice similar to GH, but unlike GH, GHv promoted growth without inhibiting insulin action and without promoting growth of PRLR-positive cancers in vitro. Thus, GHv may represent improvements to current GH therapies especially for individuals at risk for metabolic syndrome or PRLR-positive cancers. growth hormone, placental growth hormone, growth hormone variant, growth hormone 2, GH-V, GH-2 This content is only available as a PDF. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Reference Key
o2001endocrinologythe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors List, Edward, O;Berryman, Darlene, E;Basu,, Reetobrata;Buchman,, Mathew;Funk,, Kevin;Kulkarni,, Prateek;Duran-Ortiz,, Silvana;Qian,, Yanrong;Jensen, Elizabeth, A;Young, Jonathan, A;Yildirim,, Gozde;Yakar,, Shoshana;Kopchick, John, J;
Journal endocrinology
Year 2001
DOI
DOI not found
URL
https://www.deepdyve.com/doc-view?docId=10.1210/endocr/bqaa097&fieldName=journal_doi&affiliateId=OUP
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.